TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.
Karen Lisa SmithCarolyn Mead-HarveyGina L MazzaEileen H ShinnElizabeth S FrankMichelle E MeliskoCyd EatonYisi LiuJeannine M SalamoneTeri PollastroPatricia A SpearsNicole E CastonAntonio C WolffGabrielle Betty RocquePublished in: Cancer medicine (2024)
While pandemic-related anxiety was associated with diminished willingness to participate in trials, the leading reasons for reluctance to consider trial participation were unrelated to the pandemic but included worries about not getting the best treatment, side effects, and delaying care. Patients view trial modifications favorably, supporting continuation of these modifications, as endorsed by the National Cancer Institute and others.
Keyphrases
- sars cov
- coronavirus disease
- clinical trial
- phase ii
- phase iii
- end stage renal disease
- study protocol
- newly diagnosed
- ejection fraction
- healthcare
- palliative care
- peritoneal dialysis
- prognostic factors
- papillary thyroid
- physical activity
- randomized controlled trial
- cross sectional
- quality improvement
- squamous cell
- sleep quality
- squamous cell carcinoma
- patient reported
- drug induced
- lymph node metastasis